Circulating metabolic biomarkers consistently predict incident type 2 diabetes in Asian and European populations – a plasma metabolomics analysis of four ethnic groups

Jowy Yi Hoong Seah[1*], Yueheng Hong[1*], Anna Cichońska[2*], Charumathi Sabanayagam[3, 4], Simon Nusinovici[3], Tien Yin Wong[3, 4, 5], Ching-Yu Cheng[3, 4, 5], Pekka Jousilahti[6], Annamari Lundqvist[6], Markus Perola[6,7], Veikko Salomaa[6], E. Shyong Tai[1, 4, 5], Peter Würtz[2], Rob M. van Dam[1, 8†], Xueling Sim[1†]

[1]Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore; Singapore 117549, Singapore

[2]Nightingale Health Ltd, Mannerheimintie 164a, 00300 Helsinki, Finland

[3]Singapore Eye Research Institute, Singapore National Eye Centre, Singapore 169856, Singapore

[4]Duke-NUS Medical School, Singapore 169857, Singapore

[5]Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore 117597, Singapore

[6]Department of Public Health Solutions, Finnish Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland

[7]Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.

[8]Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, Washington, DC 20052.

*These authors contributed equally.

†These authors are co-corresponding senior authors.

Rob M. van Dam. [8]Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, 950 New Hampshire Ave NW, Washington, DC 20052; tel: +1 202 994 8490; e-mail: rvandam@gwu.edu

Xueling Sim. Saw Swee Hock School of Public Health, 12 Science Drive 2, #10-01, Singapore 117549; tel: +65 6601 5096; e-mail: ephsx@nus.edu.sg

Number of figures (to print, not Supplementary data): 1

Number of tables (to print, not Supplementary data): 2

Supplementary data submitted: 6 tables

Running title: Metabolic biomarkers and type 2 diabetes

Abbreviations: ARIC, Atherosclerosis Risk in Communities, BCAA, branched-chain amino acids, BMI, body mass index, GlycA, glycoprotein acetyls, HbA1c, glycated hemoglobin, HDL, high-density lipoprotein, IDL, intermediate-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, MUFA, monounsaturated fat, NMR, nuclear magnetic resonance, PUFA polyunsaturated fat, SEED, Singapore Epidemiology of Eye Diseases, SFA, saturated fat, T2D, type 2 diabetes, VLDL, very low-density lipoprotein

Word count: 4155 (Introduction to Discussion)

Abstract

Background: Persons of Asian ethnicity have a higher risk of type 2 diabetes (T2D) and tend to develop the disease at a lower age and level of adiposity than those of European ethnicity. It remains unclear whether the same markers of metabolic pathways are associated with the development of diabetes in Asian and European ethnic groups. We therefore evaluated the relation between metabolic biomarkers and incident T2D in three major Asian ethnic groups (Chinese, Malay, and Indian) and a European population.

Methods and Findings: We used data from male and female adult participants of two cohorts from Singapore (n = 6,393 Asians) consisting of ethnic Chinese, Malays, and Indians, and three cohorts of European-origin participants from Finland (n = 14,558). We used nuclear magnetic resonance to quantify 154 metabolic biomarkers in plasma collected at baseline and performed multivariable logistic regression to assess associations between the metabolic measures and risk of T2D with adjustments for age, sex, BMI and either fasting glucose or glycated haemoglobin (HbA1c). Of the 154 metabolic biomarkers, 59 were associated with a higher risk of T2D in both Asians and Europeans ($P < 0.0003$; Bonferroni-corrected). These included branched-chain and aromatic amino acids and alanine, the inflammatory marker glycoprotein acetyls, total fatty acids, the proportion of monounsaturated fatty acids, apolipoprotein B, larger very low-density lipoprotein particle sizes, and triglycerides. A further 13 metabolic biomarkers were associated with a lower T2D risk in both Asians and Europeans including the proportion of omega-6 polyunsaturated fatty acids and larger high-density lipoprotein particle sizes. Associations were consistent within the Asian ethnic groups ($P_{het} \geq 0.05$ for all 154 metabolic biomarkers) and largely consistent for the Asian and European population ($P_{het} \geq 0.05$ for 128 of 154 metabolic biomarkers).

Conclusions: Metabolic biomarkers across a variety of biological pathways were consistently associated with T2D risk in three Asian ethnic groups and a European population.

Keywords: NMR, metabolomics, type 2 diabetes, branched-chain amino acids, aromatic amino acids, glycoprotein acetyls, inflammation, fatty acids, lipoprotein, HDL, LDL, triglycerides, cholesterol

Introduction

The global burden of type 2 diabetes (T2D) is high and rising [1, 2], with the prevalence expected to rise to 7079 cases per 100,000 in 2030, from 6059 cases per 100,000 in 2017 [2]. In randomized trials, pharmaceutical and lifestyle interventions substantially reduced the risk of T2D [3-5] in high-risk individuals. Variation in genetic, environmental and lifestyle exposures between individuals, coupled with heterogeneity in T2D [6, 7] has motivated omics biomarkers as intermediate phenotypes to T2D and the development of 'precision medicine' approaches to prevention [8-10]. Metabolic biomarkers reflect the dynamic and ongoing state of homeostasis and metabolism [11]. In recent years, the field of metabolomics has gained traction due to technological advances [12] and has uncovered various metabolites that are consistent predictors of T2D [13]. As many of these metabolic biomarkers are modifiable by diet or other lifestyle factors, information on metabolic risk factors may guide personalized interventions.

Previous studies on metabolic profiles and T2D risk were mostly conducted in populations of predominantly European ancestry, and it remains unclear if these findings can be generalized to different Asian ethnic groups. For example, individuals of Asian origin tend to develop T2D at a lower body mass index (BMI) and a younger age than those of European origin [7], and ethnic Indians are generally more insulin resistant than ethnic Malays or Chinese [14]. Although some metabolomics studies on T2D incidence have been conducted in East Asian (e.g. Chinese) populations, data on South East Asian (e.g. Malays) and South Asian (e.g. Indians) populations are limited.

We therefore evaluated whether associations between biomarkers reflecting a variety of biological pathways and diabetes incidence differed between Asian and European ethnic groups. We quantified amino acids, an inflammatory marker, fatty acids, lipoprotein and ketone bodies using nuclear magnetic resonance (NMR) metabolomic analysis in two multi-ethnic cohorts in Singapore and three cohorts in Finland. NMR metabolomics allows for highly reproducible identification and quantification of compounds [15, 16]. We subsequently performed association analyses of these metabolic measures with risk of T2D in three major Asian ethnic groups (Chinese, Malay, and Indian) and the European population.

Methods

Study Population

The Asian participants included in this study were from two population-based cohorts in Singapore that included ethnic Indians, Malays and Chinese: the Multiethnic Cohort (MEC) [17] study and the Singapore Epidemiology of Eye Diseases (SEED) cohort study [18, 19]. The European participants in our study were from three Finnish prospective population-based cohorts (FINRISK 2002, FINRISK 2012 and Health 2000) [20, 21]. All studies included questionnaires about socio-demographic characteristics and medical history, technician-measurement of anthropometric measures and blood pressure, and collection of blood samples. Details of the individual cohorts are provided in the **Supplemental Text**. Informed consent was obtained from all participants and ethical approvals were obtained from the respective ethics review boards.

For all cohorts, we excluded participants with diabetes, cardiovascular diseases or cancer at baseline. From the MEC cohort of 9180 participants, we identified 694 incident diabetes cases using the following criteria: (a) fasting plasma glucose ≥7.0 mmol/L or HbA1c ≥6.5 % (47.5 mmol/mol) based on the American Diabetes Association [22] or self-reported physician-diagnosed diabetes at follow-up, or (b) record linkage with a national database of medical diagnoses as part of public hospital, polyclinic, and subsidized GP visits). Using risk-set sampling, we selected 1315 controls matched for age (±5 years), sex, date of health screening (±2 years), and ethnicity from cohort participants who were alive, and did not have diabetes at the time the index case occurred. We used 6-year revisit data from 4384 SEED cohort participants among whom 391 developed diabetes during follow-up. Diabetes ascertainment at baseline and the revisit was based on random plasma glucose ≥11.1 mmol/L or HbA1c ≥6.5 % (47.5 mmol/mol) [22], or a self-reported physician diagnosis. For the European cohorts, we used data on 14588 participants from FINRISK 2002, FINRISK 2012 and Health 2000, among whom 1055 developed diabetes during follow-up. Diabetes ascertainment at baseline was based on the National Social Insurance Institution Drug Purchase and Reimbursement Registries for purchases and reimbursements of purchases of hypoglycemic drugs, and the National Hospital Discharge Register for hospitalizations with diabetes as the diagnosis. Incident diabetes cases were identified by linking the participants to the registers described above with a unique personal identification code assigned to each Finnish citizen. Participants with prevalent or incident gestational diabetes were excluded.

Metabolic Biomarker Quantification and Quality Control

Metabolic biomarkers were quantified from plasma samples at baseline using a high-throughput ^{1}H-NMR metabolomics platform developed by Nightingale Health Ltd. (Helsinki, Finland; nightingalehealth.com/; biomarker quantification version 2016). Details of the procedure have been described previously [23, 24]. The metabolic biomarkers quantified reflected several etiologically diverse pathways, such as amino acids, fatty acids, ketone bodies, and gluconeogenesis related measurements. In addition, lipoprotein measures including total concentration, total lipids, phospholipids, total cholesterol, cholesterol esters, free cholesterol and triglycerides within 14 lipoprotein subclasses were measured. 9 MEC and 20 SEED participants had >10% missing metabolic biomarker values and were excluded from subsequent analyses. For participants with metabolic biomarker values lower than detection level, we replaced values of 0 with a value equivalent to 0.9 multiplied by the non-zero minimum value of that measurement. Finally, we standardized the metabolic biomarker concentrations to z-scores, and all effect sizes were reported as per standard deviation increment to enable comparison of metabolic biomarker associations for measures with different units and concentration ranges. A total of 154 individual metabolic biomarkers were included in our analyses.

Statistical analyses

We first calculated Pearson's correlation coefficients for all 154 metabolic biomarkers. Logistic regression was then used to assess associations between circulating metabolic biomarkers with T2D. For the matched MEC case-control study, conditional logistic regression model was used. In all studies, we adjusted for baseline age, sex, BMI, and fasting glucose (for MEC and Health 2000) or glycated hemoglobin (HbA1c, for non-fasting SEED, FINRISK 2002 and 2012 cohorts). For

MEC, age^2 was included in the conditional logistic model as there was evidence of non-linearity in the relationship between age and T2D risk. Logistic models were performed separately by study and ethnic group to account for differences between populations. Inverse variance-weighted fixed-effect meta-analysis was used to first pool ethnic-specific association statistics from the two Singapore cohorts, and then to combine association results from three ethnic groups. We also tested for heterogeneity using the Cochran Q heterogeneity. Bonferroni correction was used to account for multiple testing of 154 metabolic biomarkers and P <0.0003 (0.05/154) was considered statistically significant.

To test the joint effects of multiple metabolic biomarkers on risk of T2D, we considered pairwise correlations between the metabolic biomarkers from MEC (Supplement Table 1). For the set of T2D associated metabolic biomarkers in the association analysis above that considered a metabolic biomarker individually across Asian and European populations, we first sorted the metabolic biomarkers by their strength of association. Starting with the most significantly associated metabolic biomarker (index-associated metabolic biomarker), we iteratively excluded other associated metabolic biomarkers that had correlations ≥ 0.80 with the index-associated metabolic biomarker (correlation-pruning). The set of remaining metabolic biomarkers thus had a Bonferroni-adjusted significant association with T2D and pairwise correlations <0.80. Finally, we performed stepwise regression analysis with the criterion of P-value of 0.05 in a joint model that included the selected biomarkers in the Asian and European cohorts. All statistical analyses were conducted using R 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).

Results

In the nested MEC case-control study, 694 incident T2D cases and 1315 matched controls were included in this study during a mean follow-up of 6.9 y (standard deviation SD: 2.4 y), and in the SEED cohort study, 391 incident T2D cases occurred in 4384 participants during an average of 6.2 y (SD: 1.1 y). In the European cohorts, 1055 incident T2D cases occurred in 14,558 participants during an average of 11.3 years (SD: 5.0 y). The average age was 54.0 y (SD: 9.8 y) for the Asian participants and 50.6 y (SD: 14.1 y) for the European participants, with similar representation of males and females for all populations, and Chinese, Malays and Indians for the Asian population (**Table 1**).

We observed high correlations among the branched-chain amino acids (BCAAs) leucine, isoleucine and valine, and concentrations of n-6 polyunsaturated (n-6 PUFA) fatty acids, PUFA, monounsaturated fatty acids (MUFA), saturated fatty acids and linoleic acid (18:2n-6) (all r>0.80) (**Supplemental Tables 1 to 4**). In general, the lipid components (total lipids, phospholipids, cholesterol esters, free cholesterol) with the exception of triglycerides within a particular lipoprotein subclass were also highly correlated. Overall, 59 of the 154 metabolic biomarkers were consistently associated with a higher risk and 13 with a lower risk of T2D in both Asians and Europeans ($P_{meta} < 0.0003$; Bonferroni-corrected; $P_{\text{het}} < 0.05$ for 12 metabolic biomarkers) (**Table 2, Figure 1** and **Supplemental Table 5)** after adjustment for age, sex, BMI and either fasting glucose or HbA1c. For the population-specific meta-analysis, we observed little heterogeneity in association across the three Asian ethnic groups ($P_{\text{het}} \geq 0.05$ for all 154 metabolic biomarkers) and across the three European cohorts ($P_{\text{het}} \geq 0.05$ for 144 of 154 metabolic biomarkers). Of the 29 metabolic biomarkers for which

we did observe evidence for heterogeneity between the Asian and European populations, 23 were lipoprotein measures.

Amino Acids and Inflammation

Higher concentrations of BCAAs (leucine, isoleucine, and valine), aromatic amino acids (phenylalanine and tyrosine), and alanine were significantly and consistently associated with higher T2D risk in both Asians and Europeans (all $P_{het} > 0.05$). The strongest association was observed for leucine (Asians: OR 1.50 per 1 SD increment, 95% CI 1.35 - 1.66; Europeans: OR 1.36, 95% CI 1.27 - 1.46). The inflammatory marker glycoprotein acetyls (GlycA) was also directly associated with risk of T2D (Asians: OR 1.41, 95% CI 1.28 - 1.55; Europeans: OR 1.34, 95% CI 1.25 - 1.43; $P_{het} = 0.37$). GlycA remained directly associated with T2D risk after further adjustments for CRP (data available only for MEC and the European cohorts, Asians: OR 1.94, 95% CI 1.63 - 2.31; Europeans: OR 1.34, 95% CI 1.25 - 1.44).

Fatty Acids

Higher total concentrations of fatty acids in plasma were significantly associated with higher T2D risk. Among the different types of fatty acids, a higher proportion of MUFA was consistently associated with a higher T2D risk (Asians: OR 1.43, 95% CI 1.30 - 1.57; Europeans: OR 1.38, 95% CI 1.27 - 1.51), and a higher proportion of n-6 PUFA with a lower risk (Asians: OR 0.70, 95% CI 0.64 - 0.77; Europeans: OR 0.70, 95% CI 0.65 - 0.75). The proportion of saturated fat (SFA) was directly associated with T2D risk, but this was not statistically significant after Bonferroni correction in Asians (Asians: OR 1.15, 95% CI: 1.05 - 1.25; Europeans: OR 1.21, 95% CI 1.13 - 1.29). n-3 PUFAs were not significantly associated with risk of T2D in any ethnic

group. There was no evidence of heterogeneity for associations of fatty acids with T2D between the Asian and European populations (all $P_{het} > 0.05$).

Lipoprotein Measures

We evaluated lipoprotein particle sizes, apolipoproteins and various lipoprotein measures including total concentrations, total lipids, phospholipids, total cholesterol, cholesterol esters, free cholesterol and triglycerides for 14 lipoprotein subclasses, in relation to T2D (**Figure 1** and **Supplemental Table 5**).

Higher levels of apolipoprotein B were associated with higher T2D risk in both Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30; $P_{het} = 0.45$). Larger VLDL particle size was among the metabolic biomarkers with the strongest direct associations with T2D risk (Asians: OR 1.44, 95% CI 1.31 - 1.59; Europeans: OR 1.46, 95% CI 1.36 - 1.57; $P_{het} = 0.83$). Larger LDL particle sizes were inversely associated with incident T2D risk in Europeans (OR 0.82, 95% CI 0.76 - 0.89), but not in Asians (Asians: OR 0.98, 95% CI 0.89 - 1.07; $P_{het} = 0.01$). Larger HDL particle sizes were also more strongly inversely associated with T2D risk in Europeans (OR 0.63, 95% CI 0.58 - 0.69) as compared with Asians (OR 0.77, 95% CI 0.69 - 0.86; $P_{het} = 0.01$).

The concentration of cholesterol in very low-density lipoprotein (VLDL) particles was generally associated with higher risk of T2D in both Asians and Europeans (all $P_{het} > 0.05$), with the strongest association observed for cholesterol in large VLDL particles (Asians: OR 1.41, 95% CI 1.29 - 1.53; Europeans: OR 1.29, 95% CI 1.22 - 1.37; $P_{het} = 0.10$). Because the lipid components (total lipids, phospholipids,

cholesterol esters, free cholesterol, triglycerides) in VLDL particles were highly correlated (**Supplemental Tables 1 to 4**), particularly in extremely large VLDL, very large VLDL, large VLDL and medium VLDL (Pearson's r>0.85), these lipid components were similarly associated with T2D risk as VLDL cholesterol.

Total high-density lipoprotein (HDL) cholesterol was inversely associated with T2D risk in Asians (OR 0.85, 95% CI 0.76 - 0.94) and Europeans (OR 0.76, 95% CI 0.69 - 0.82; P_{het} = 0.09), although this did not reach Bonferroni-corrected significance in Asians. These inverse associations appeared to be driven by cholesterol in very large and large HDL particles, which were stronger in Europeans than in Asians (very large HDL: P_{het}=0.02; large HDL: P_{het}=0.04). Other lipid components of HDL (total lipids, phospholipids, cholesterol esters, free cholesterol) with the exception of triglycerides were similarly associated with T2D risk as the cholesterol component of HDL. There were no significant associations between intermediate-density lipoprotein (IDL) cholesterol and low-density lipoprotein (LDL) cholesterol concentrations and T2D risk.

Elevated concentrations of total triglycerides were significantly associated with a higher risk of T2D in Asians (OR 1.43, 95% 1.31 - 1.57) and Europeans (OR 1.32, 95% CI 1.25 - 1.40; P_{het} = 0.14). Results were similar when we analyzed triglycerides in subclasses of VLDL, LDL, and HDL, with the exception of triglycerides in large HDL.

Other Metabolic Biomarkers

We also evaluated ketone bodies, glycerides, phospholipids, and metabolites related to glycolysis and fluid balance (**Table 2**). Higher phosphoglyceride concentrations were associated with T2D risk but this remained significant after Bonferroni correction only in Asians (OR 1.18, 95% CI 1.08 - 1.30) and not in Europeans (OR 1.08, 95% CI 1.01, 1.16; $P_{\text{het}} = 0.14$). Similarly, higher albumin concentrations were significantly associated with a higher risk of T2D in Asians (OR 1.23, 95% CI: 1.12 - 1.35), but not Europeans (OR 1.12, 95% CI 0.97 - 1.28; $P_{\text{het}} = 0.25$).

Joint Effects of Metabolic Biomarkers on Risk of T2D

Using the correlation-pruning method, 12 metabolic biomarkers in MEC were significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA, unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small VLDL particle concentration, and very large HDL phospholipids. Stepwise regression selected a multivariable model that simultaneously included isoleucine, GlycA, unsaturation index, and very large HDL phospholipids (**Supplemental Table 6**). Higher levels of isoleucine (Asians: OR 1.25, 95% CI 1.10 - 1.42; Europeans: 1.18, 95% CI 1.06 - 1.31) and GlycA (Asians: OR 1.17, 95% CI 1.03 - 1.33; Europeans: OR 1.06, 95% CI 0.95 - 1.18) were associated with higher T2D risk, and very large HDL phospholipids with lower T2D risk (Asians: OR 0.88, 95% CI 0.77 - 0.99; Europeans: OR 0.70, 95% CI 0.62 - 0.78). There was no independent significant association between unsaturation index and T2D risk. We observed evidence of heterogeneity between the Asian and European populations only for very large HDL phospholipids ($P_{\text{het}} = 0.01$).

Discussion

We quantified 154 metabolic biomarkers using NMR technology in plasma samples from five prospective cohort studies representing three major ethnic groups in Asia (Chinese, Malay, and Indian) and a European population. While there have been previous metabolomics studies in Asians and individuals of European descent, these were mostly conducted separately in ethnically homogenous populations with cross-sectional study design, different metabolomics platforms or statistical methods that did not facilitate direct comparison of results [13, 25]. Here, we report that branched-chain amino acids, aromatic amino acids, alanine, the inflammatory marker GlycA, total fatty acids, the proportion of MUFA, apolipoprotein B, larger VLDL particle sizes and triglycerides were consistently associated with a higher T2D risk in Asians and Europeans. Furthermore, the proportion of n-6 PUFA and larger HDL particle sizes were consistently associated with a lower T2D risk in Asians and Europeans. Overall, associations were consistent across the Asian ethnic groups, and largely consistent for the Asian and European populations.

Our finding that higher concentrations of BCAAs (leucine, isoleucine and valine) were associated with a higher risk of T2D is consistent with the results of previous prospective studies [13, 23, 25-30]. Results from Mendelian randomization studies suggest that BCAA metabolites play a causal role in the pathogenesis of T2D [30]. In line with our results, the aromatic amino acids phenylalanine and tyrosine were directly associated with T2D risk in a meta-analysis of prospective studies [13], and alanine was directly associated with T2D risk in a Japanese cohort [27]. Elevated concentrations of aromatic amino acids and alanine have been hypothesized to induce

insulin resistance, possibly by inhibition of glucose transport and phosphorylation in skeletal muscle [13, 31, 32].

A higher concentration of the inflammatory marker GlycA was associated with a higher risk of T2D in our study, which is compatible with results from the Dutch PREVEND study and the U.S. Women's Health Study [33, 34]. GlycA is a composite NMR measure that arises from the *N*-acetyl methyl group protons of oligosaccharide moieties of acute-phase proteins [35], proteins whose concentrations change in response to inflammation. As opposed to CRP, which is characterized by multi-fold elevation in acute state, GlycA levels fluctuate less on short-term bases and may therefore capture different aspects of the inflammatory response [36], a hypothesis supported by our results and results of the PREVEND study as GlycA remains directly associated with T2D risk after adjusting for CRP [33]. However, in the Women's Health Study, the association between GlycA and incident T2D was significantly attenuated after adjusting for CRP [34]. It is plausible that low-grade inflammation is involved in the pathogenesis of T2D through insulin resistance and beta-cell dysfunction [37, 38].

Our report of a direct association between plasma MUFA and T2D risk is consistent with a previous finding in a Finnish cohort [39], but not with the Atherosclerosis Risk in Communities (ARIC) study [40]. Because MUFA can be synthesized endogenously from SFA [41], plasma MUFAs concentrations may reflect SFA intake. We also observed a direct association between plasma SFA and T2D risk although this was not significant in Asians. In the ARIC study [40] and a Finnish cohort [39], a higher proportion of SFA was also associated with higher T2D risk. It has been hypothesized

that high plasma SFAs promote insulin resistance and are lipotoxic to beta-cells [42, 43]. Our study further showed that higher proportions of n-6 PUFAs were associated with a lower risk of T2D, concordant with a previous meta-analysis of prospective cohort studies [44]. The association may be partly mediated by increasing insulin sensitivity through increasing cellular membrane fluidity [45, 46], particularly of skeletal muscle cells and hepatocytes [45, 46], and by acting as ligands for peroxisome proliferator-activated receptor gamma [47, 48]. These hypotheses are supported by a meta-analysis of randomized feeding trials that showed improvements in glucose-insulin homeostasis for dietary PUFA compared to SFA or MUFA [49]. In a recent Mendelian randomization study, genetic predisposition to higher levels of linoleic acid was associated with a lower risk of T2D [50], supporting a causal effect of linoleic acid on T2D. The lack of association between the relative fraction of n-3 PUFA and T2D risk is consistent with a previous meta-analysis of prospective studies [51].

We also identified several patterns in the lipoprotein profile that were consistently associated with T2D risk across ethnic groups. Larger VLDL particles were directly associated with T2D risk, similar to existing evidence from prospective studies [23, 52-54]. VLDL is mostly comprised of triglycerides, and larger particles carry more triglycerides [54]. The causal relationship between plasma triglycerides and T2D is still a matter of debate [55] and there was no consensus among studies on genetically influenced triglyceride levels and T2D incidence [56, 57]. Our finding that the concentration of larger HDL particles was inversely associated with T2D risk also agrees with previous prospective studies in western populations [23, 52-54]. While HDL lipid components (e.g. phospholipids, cholesterol esters, free cholesterol) in very

large and large HDL particles were associated with lower risk of T2D, they were not associated with T2D risk in medium and small HDL particles. This suggests that the inverse associations observed for HDL lipid components were driven by particle size rather than lipid composition. Larger HDL particles have been hypothesized to be more efficient in cholesterol efflux capacity than smaller HDL particles [58, 59]. HDL particles may also have other anti-diabetic properties such as promoting insulin secretion and glucose uptake in skeletal muscle cells [60].

Our study's strengths included the use of large population-based cohorts collected in diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for heterogeneity between populations. However, we also acknowledge certain limitations. First, a limitation of NMR technology compared to MS is its lower sensitivity, and we could not quantify metabolic biomarkers that were below the detection limit of NMR. Second, participants of the SEED cohorts were not required to fast and this may have affected levels of certain metabolic biomarkers such as triglycerides and amino acids [61, 62]. However, this would have more likely weakened than strengthened the observed associations. Third, different T2D case ascertainments were used for the cohorts and this may have affected comparability of the results. However, despite different methodologies in case ascertainments, we obtained consistent results across the different cohorts. Finally, we cannot rule out residual confounding due to unmeasured or imperfectly measured risk factors.

Our results may have implications in clinical practice, including the prevention and treatment, and early detection and prognosis of T2D. The metabolic biomarkers

associated with T2D risk in our study are modifiable and may thus provide targets for lifestyle and pharmacological interventions for prevention and treatment. For example, replacing dietary SFA with PUFA has long been part of dietary recommendation to reduce cardiovascular disease risk [63] and may also reduce T2D risk by improving plasma fatty acid profiles. Similarly, dietary BCAAs and aromatic amino acids are primarily from animal products, such as meat, and lower consumption may reduce T2D risk partly by improving circulating amino acids [64-66] and insulin sensitivity [67]. Furthermore, cholesteryl ester transfer protein inhibitors are a drug class that is known to preferentially increase larger HDL particles [68, 69]. In a meta-analysis of four randomized trials, these drugs significantly reduced T2D risk although it is unclear if this effect is caused solely by changes in circulating HDL [68-70]. Because these metabolic biomarkers reflect modifiable pathways, metabolic profiling data could inform ‘precision medicine’ approaches that prioritize specific preventive interventions for individuals at high risk of T2D. Various biomarkers such as BCAAs and aromatic amino acids may be etiologically involved in insulin resistance [31, 71], and the inclusion of these biomarkers to prediction models of T2D improved area under curve (AUC) [72]. As the biological pathways involved in the pathogenesis of T2D appear to be similar in Asians and Europeans, these interventions and approaches for detection and prediction may be effective for both populations.

Several physiological differences have been proposed to contribute to the higher susceptibility to developing T2D in Asians than Europeans [7]. For example, greater visceral adiposity and less lean body mass may contribute to the higher rates of T2D in South Asians as compared with European ancestry populations [7, 73, 74]. The

generally consistent associations for metabolic biomarkers across diverse ethnic groups in our study suggest that differences in the degree of metabolic disturbances in the evaluated pathways rather than differences in the pathways involved contribute to ethnic differences in risk of T2D. However, there may be exceptions for selected biological pathways. For example, South Asians have been found to have smaller mean HDL particle sizes as compared with European ancestry populations [75] and this may contribute to the higher risk of T2D in South Asians through less efficient reverse cholesterol transport and dyslipidemia [58]. Our observation of possibly stronger inverse associations between HDL and T2D risk in Europeans than Asians, particularly for very large HDL, is novel and warrants further studies.

We found consistent associations between metabolic signatures and risk of T2D in prospective cohorts in Asia and Europe. Metabolic aberrations that spanned multiple pathways, including amino acids, inflammation, fatty acids and lipoproteins were similarly associated with T2D risk in major Asian ethnic groups and Europeans despite environmental, lifestyle, and physiological differences. Our results suggest that these are candidates for better prediction of T2D in different ethnic groups that require further evaluation in prognostic studies. Moreover, these metabolic biomarkers are modifiable and may be targets for preventive interventions across different ethnic groups. Metabolic profiles may inform future personalized interventions for the prevention of T2D in increasingly cosmopolitan populations.

Acknowledgements

All authors have no conflicts of interest.

CS, SN, TYW, C-YC, PJ, AL, MP, VS, EST, PW, RMvD and XS and conceived and designed research. AC and PW conducted experiments. CS, SN, TYW, C-YC, PJ, AL, MP, VS, EST, PW and RMvD contributed data. JYHS, YH, AC and XS analyzed data. JYHS, RMvD and XS wrote the manuscript and had primary responsibility for final content. All authors read and approved the manuscript.

The authors thank all investigators, staff members, and study participants for their contributions to all the participating studies. The MEC is supported by grants from the Singapore Ministry of Health, including National Medical Research Council Large Collaborative Grant (MOH-000271-00), National University of Singapore and National University Health System, Singapore. Metabolic profiling for MEC was supported by NUHS Summit Research Program (Metabolic Diseases) and performed by Nightingale Health Ltd. The SEED cohorts are supported by the National Medical Research Council (NMRC), Singapore (grants 0796/2003, 1176/2008, 1149/2008, STaR/0003/2008, 1249/2010, CG/SERI/2010, CIRG/1371/2013, CIRG/1417/2015, CIRG/1488/2018 and OFLCG/004a/2018), and Biomedical Research Council (BMRC), Singapore (08/1/35/19/550 and 09/1/35/19/616). VS was supported by the Finnish Foundation for Cardiovascular Research. JYHS was supported by the Singapore Ministry of Health's National Medical Research Council Large Collaborative Grant (MOH-000271-00).

Disclosures

A. Cichońska and P. Wu□rtz are employees and shareholders of Nightingale Health Ltd., a company offering NMR-based biomarker profiling.

B. VS has received honoraria for consulting for Novo Nordisk and Sanofi. He also has ongoing research collaboration with Bayer Ltd (All unrelated to the present study).

Data availability

Data described in the manuscript, code book and analytic code will be made available upon request pending application and approval.

References

1. Nanditha, A., et al., *Diabetes in Asia and the Pacific: Implications for the Global Epidemic.* Diabetes Care, 2016. **39**(3): p. 472-485.
2. Khan, M.A.B., et al., *Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends.* Journal of Epidemiology and Global Health, 2020. **10**(1): p. 107-111.
3. Uusitupa, M., et al., *Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis.* Nutrients, 2019. **11**(11).
4. Gillies, C.L., et al., *Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.* British Medical Journal, 2007. **334**(7588): p. 299-302B.
5. Sheng, Z., et al., *Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis.* Frontiers in Endocrinology, 2019. **10**.
6. Kodama, K., et al., *Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response A systematic review and meta-analysis.* Diabetes Care, 2013. **36**(6): p. 1789-1796.
7. Chan, J.C.N., et al., *Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology.* Jama-Journal of the American Medical Association, 2009. **301**(20): p. 2129-2140.
8. Philipson, L.H., *Harnessing heterogeneity in type 2 diabetes mellitus.* Nature Reviews Endocrinology, 2020. **16**(2): p. 79-80.

9. Prasad, R.B. and L. Groop, *Precision medicine in type 2 diabetes.* Journal of Internal Medicine, 2019. **285**(1): p. 40-48.

10. Palmnäs, M., et al., *Perspective: Metabotyping-A Potential Personalized Nutrition Strategy for Precision Prevention of Cardiometabolic Disease.* Adv Nutr, 2020. **11**(3): p. 524-532.

11. Wishart, D.S., *Emerging applications of metabolomics in drug discovery and precision medicine.* Nature Reviews Drug Discovery, 2016. **15**(7): p. 473-484.

12. Putri, S.P., et al., *Current metabolomics: Technological advances.* Journal of Bioscience and Bioengineering, 2013. **116**(1): p. 9-16.

13. Guasch-Ferre, M., et al., *Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.* Diabetes Care, 2016. **39**(5): p. 833-846.

14. Gao, H., et al., *Can body fat distribution, adiponectin levels and inflammation explain differences in insulin resistance between ethnic Chinese, Malays and Asian Indians?* International Journal of Obesity, 2012. **36**(8): p. 1086-1093.

15. Markley, J.L., et al., *The future of NMR-based metabolomics*. Current Opinion in Biotechnology, 2017. **43**: p. 34-40.

16. Marshall, D.D. and R. Powers, *Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics.* Progress in Nuclear Magnetic Resonance Spectroscopy, 2017. **100**: p. 1-16.

17. Tan, K.H.X., et al., *Cohort Profile: The Singapore Multi-Ethnic Cohort (MEC) study.* Int J Epidemiol, 2018.

18. Lavanya, R., et al., *Methodology of the Singapore Indian Chinese Cohort (SICC) Eye Study: Quantifying ethnic variations in the epidemiology of eye diseases in Asians.* Ophthalmic Epidemiology, 2009. **16**(6): p. 325-336.

19. Rosman, M., et al., *Singapore Malay Eye Study: rationale and methodology of 6-year follow-up study (SiMES-2).* Clinical and Experimental Ophthalmology, 2012. **40**(6): p. 557-568.

20. Borodulin, K., et al., *Cohort Profile: The National FINRISK Study*. International Journal of Epidemiology, 2018. **47**(3): p. 696-+.

21. Pirkola, S.P., et al., *DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population - Results from the Health 2000 Study*. Social Psychiatry and Psychiatric Epidemiology, 2005. **40**(1): p. 1-10.

22. American Diabetes Association, *Diagnosis and classification of diabetes mellitus.* Diabetes Care, 2010. **33 Suppl 1**: p. S62-9.

23. Ahola-Olli, A.V., et al., *Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts.* Diabetologia, 2019. **62**(12): p. 2298-2309.

24. Soininen, P., et al., *Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics*. Circulation-Cardiovascular Genetics, 2015. **8**(1): p. 192-206.

25. Tillin, T., et al., *Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study*. Diabetologia, 2015. **58**(5): p. 968-979.

26. Flores-Guerrero, J.L., et al., *Plasma Branched-Chain Amino Acids and Risk of Incident Type 2 Diabetes: Results from the PREVEND Prospective Cohort Study*. Journal of Clinical Medicine, 2018. **7**(12).

27. Chen, S.M., et al., *Serum amino acid profiles and risk of type 2 diabetes among Japanese adults in the Hitachi Health Study.* Scientific Reports, 2019. **9**.

28. Satheesh, G., S. Ramachandran, and A. Jaleel, *Metabolomics-Based Prospective Studies and Prediction of Type 2 Diabetes Mellitus Risks.* Metabolic Syndrome and Related Disorders, 2020. **18**(1): p. 1-9.

29. Lu, Y.H., et al., *Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS.* Diabetologia, 2016. **59**(11): p. 2349-2359.

30. Lotta, L.A., et al., *Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis.* Plos Medicine, 2016. **13**(11).

31. Wurtz, P., et al., *Branched-Chain and Aromatic Amino Acids Are Predictors of Insulin Resistance in Young Adults.* Diabetes Care, 2013. **36**(3): p. 648-655.

32. Krebs, M., et al., *Mechanism of amino acid-induced skeletal muscle insulin resistance in humans.* Diabetes, 2002. **51**(3): p. 599-605.

33. Connelly, M.A., et al., *GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study.* Clinica Chimica Acta, 2016. **452**: p. 10-17.

34. Akinkuolie, A.O., et al., *Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus.* Arterioscler Thromb Vasc Biol, 2015. **35**(6): p. 1544-50.

35. Connelly, M.A., et al., *GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk.* Journal of Translational Medicine, 2017. **15**.

36. Ritchie, S.C., et al., *The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection.* Cell Systems, 2015. **1**(4): p. 293-301.

37. Hameed, I., et al., *Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition.* World Journal of Diabetes, 2015. **6**(4): p. 598-612.

38. Jin, C.C., J. Henao-Mejia, and R.A. Flavell, *Innate Immune Receptors: Key Regulators of Metabolic Disease Progression.* Cell Metabolism, 2013. **17**(6): p. 873-882.

39. Mahendran, Y., et al., *Glycerol and Fatty Acids in Serum Predict the Development of Hyperglycemia and Type 2 Diabetes in Finnish Men*. Diabetes Care, 2013. **36**(11): p. 3732-3738.

40. Wang, L., et al., *Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study*. American Journal of Clinical Nutrition, 2003. **78**(1): p. 91-98.

41. Nakamura, M.T. and T.Y. Nara, *Structure, function, and dietary regulation of Delta 6, Delta 5, and Delta 9 desaturases.* Annual Review of Nutrition, 2004. **24**: p. 345-376.

42. Oh, Y.S., et al., *Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes.* Frontiers in Endocrinology, 2018. **9**.

43. Sobczak, A.I.S., C.A. Blindauer, and A.J. Stewart, *Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes.* Nutrients, 2019. **11**(9).

44. Wu, J.H.Y., et al., *Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies.* Lancet Diabetes & Endocrinology, 2017. **5**(12): p. 965-974.

45. Kroger, J., et al., *Erythrocyte membrane fatty acid fluidity and risk of type 2 diabetes in the EPIC-Potsdam study.* Diabetologia, 2015. **58**(2): p. 282-289.

46. Weijers, R.N.M., *Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus.* Current Diabetes Reviews, 2012. **8**(5): p. 390-400.

47. Lai, M.C., T.H. Teng, and C. Yang, *The Natural PPAR Agonist Linoleic Acid Stimulated Insulin Release in the Rat Pancreas.* Journal of Veterinary Medical Science, 2013. **75**(11): p. 1449-1454.

48. Echeverria, F., et al., *Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging.* Prostaglandins Leukotrienes and Essential Fatty Acids, 2016. **114**: p. 28-34.

49. Imamura, F., et al., *Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled Feeding Trials.* Plos Medicine, 2016. **13**(7).

50. Yuan, S. and S.C. Larsson, *Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study.* Diabetologia, 2020. **63**(1): p. 116-123.

51. Wu, J.H.Y., et al., *Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis.* British Journal of Nutrition, 2012. **107**: p. S214-S227.

52. Mackey, R.H., et al., *Lipoprotein Particles and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis.* Diabetes Care, 2015. **38**(4): p. 628-636.

53. Hodge, A.M., et al., *NMR-determined lipoprotein subclass profile predicts type 2 diabetes.* Diabetes Research and Clinical Practice, 2009. **83**(1): p. 132-139.

54. Mora, S., et al., *Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women.* Diabetes, 2010. **59**(5): p. 1153-1160.

55. Hölzl, B., et al., *Hypertriglyceridemia and insulin resistance.* J Intern Med, 1998. **243**(1): p. 79-82.

56. De Silva, N.M., et al., *Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance.* Diabetes, 2011. **60**(3): p. 1008-18.

57. Qi, Q.B., et al., *Genetic Predisposition to Dyslipidemia and Type 2 Diabetes Risk in Two Prospective Cohorts.* Diabetes, 2012. **61**(3): p. 745-752.

58. Khera, A.V., et al., *Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).* Circulation, 2017. **135**(25): p. 2494-2504.

59. Rysz, J., et al., *The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.* International Journal of Molecular Sciences, 2020. **21**(2).

60. Drew, B.G., et al., *High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus.* Circulation, 2009. **119**(15): p. 2103-U134.

61. Jackson, K.G., S.D. Poppitt, and A.M. Minihane, *Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants.* Atherosclerosis, 2012. **220**(1): p. 22-33.

62. Ottosson, F., et al., *POSTPRANDIAL LEVELS OF BRANCH CHAINED AND AROMATIC AMINO ACIDS ASSOCIATED WITH FASTING GLYCAEMIA.* Journal of Hypertension, 2016. **34**: p. E145-E145.

63. Sacks, F.M., et al., *Dietary Fats and Cardiovascular Disease A Presidential Advisory From the American Heart Association.* Circulation, 2017. **136**(3): p. E1-+.

64. Isanejad, M., et al., *Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women's Health Initiative.* British Journal of Nutrition, 2017. **117**(11): p. 1523-1530.

65. Elshorbagy, A., et al., *Amino acid changes during transition to a vegan diet supplemented with fish in healthy humans.* European Journal of Nutrition, 2017. **56**(5): p. 1953-1962.

66. Gunther, S.H., et al., *Diet, Physical Activity and Adiposity as Determinants of Circulating Amino Acid Levels in a Multiethnic Asian Population.* Nutrients, 2020. **12**(9).

67. Karusheva, Y., et al., *Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: a randomized controlled crossover trial.* The American Journal of Clinical Nutrition, 2019. **110**(5): p. 1098-1107.

68. Krauss, R.M., et al., *Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.* Journal of Lipid Research, 2012. **53**(3): p. 540-547.

69. Kontush, A., *HDL particle number and size as predictors of cardiovascular disease.* Frontiers in Pharmacology, 2015. **6**.

70. Masson, W., et al., *Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk.* Diabetes & Metabolism, 2018. **44**(6): p. 508-513.

71. Batch, B.C., et al., *Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness.* Metabolism, 2013. **62**(7): p. 961-9.

72. Gunther, S.H., et al., *Serum acylcarnitines and amino acids and risk of type 2 diabetes in a multiethnic Asian population.* BMJ Open Diabetes Res Care, 2020. **8**(1).

73. Rush, E.C., I. Freitas, and L.D. Plank, *Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults*. Br J Nutr, 2009. **102**(4): p. 632-41.

74. Narayan, K.M.V. and A.M. Kanaya, *Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways.* Diabetologia, 2020. **63**(6): p. 1103-1109.

75. Bilen, O., A. Kamal, and S.S. Virani, *Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions.* World Journal of Cardiology, 2016. **8**(3): p. 247-257.

Legends for figures

Figure 1. Associations between baseline circulating lipoprotein measures and risk of incident type 2 diabetes. Values are ORs (95% CIs) per 1 SD increment in metabolic biomarkers levels. The results for Asian participants (n=6393) were meta-analysed using data from Chinese (n=2676), Malay (n=1872) and Indian (n=1845) participants of the MEC and the SEED cohorts which consist of the Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Results for the European participants (n=14558) were meta-analysed from 3 prospective Finnish cohorts (FINRISK 2002, FINRISK 2012 and Health 2000). We adjusted or matched for age, age^2 (only for MEC), sex, BMI and fasting glucose (MEC and Health 2000) or HbA1c (SEED cohorts, FINRISK 2002 and FINRISK 2012). We accounted for multiple testing using Bonferroni correction and *P*-values < 0.0003 were considered statistically significant. Abbreviations: ApoA1, apolipoprotein A1, ApoB, apolipoprotein B, HbA1c, glycated hemoglobin A1c, HDL, high-density lipoprotein, IDL, intermediate-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, SEED, Singapore Epidemiology of Eye Diseases, VLDL, very low-density lipoprotein

Table 1. Baseline characteristics of participants of the cohorts included in the study[1]

	MEC			SEED[2]			European cohorts		
Characteristic	**Chinese**	**Malay**	**Indian**	**Chinese**	**Malay**	**Indian**	**FINRISK 2002**	**FINRISK 2012**	**Health 2000**
No. cases / No. controls	256/499	216/411	222/405	96/1825	132/1113	163/1055	350/3904	78/4475	627/6179
Follow-up duration (y)	7.4 ± 2.5	6.7 ± 2.5	6.6 ± 2.3	5.8 ± 0.9	7.1 ± 0.9	6.0 ± 0.9	13.8 ± 0.1	3.8 ± 0.1	15.1 ± 0.1
Age at interview (y)	53.6 ± 9.5	49.1 ± 9.9	47.8 ± 10.4	57 ± 8.6	54.8 ± 10	54.4 ± 8.4	48.5 ± 13.7	48.8 ± 13.8	53.2 ± 14.2
Male [n (%)]	356 (47.1)	234 (37.3)	257 (41)	889 (46.3)	563 (45.2)	568 (46.6)	1794 (45.9)	2088 (46.7)	2748 (44.5)
Education level[3]									
Low	243 (32.2)	208 (33.2)	199 (31.8)	905 (47.1)	773 (62.2)	588 (48.4)	-	-	-
Intermediate	415 (55)	404 (64.5)	356 (56.9)	818 (42.6)	455 (36.6)	478 (39.3)	-	-	-
High	97 (12.8)	14 (2.2)	71 (11.3)	198 (10.3)	15 (1.2)	149 (12.3)	-	-	-
Body mass index (kg/m^2)	23.8 ± 3.7	26.9 ± 5	26.7 ± 4.9	23.4 ± 3.5	26 ± 4.7	25.7 ± 4.2	26.6 ± 4.5	26.6 ± 4.6	26.8 ± 4.6
Fasting glucose (mmol/L)	4.9 ± 0.6	5 ± 0.6	5.1 ± 0.6	-	-	-	-	-	5.4 ± 0.8
HbA1c (%)[4]	5.6 ± 0.4	5.6 ± 0.4	5.8 ± 0.4	5.8 ± 0.3	5.7 ± 0.4	5.7 ± 0.4	5.4 ± 0.4	5.2 ± 0.3	-
Total cholesterol (mmol/L)	5.3 ± 0.9	5.6 ± 1	5.3 ± 0.9	5.6 ± 1	5.7 ± 1.1	5.5 ± 1	5.6 ± 1.1	5.4 ± 1.0	6.0 ± 1.1
HDL cholesterol (mmol/L)	1.4 ± 0.3	1.3 ± 0.3	1.1 ± 0.3	1.4 ± 0.4	1.4 ± 0.3	1.1 ± 0.3	1.5 ± 0.4	1.5 ± 0.4	1.4 ± 0.4
LDL cholesterol (mmol/L)	3.4 ± 0.8	3.6 ± 0.9	3.5 ± 0.8	3.4 ± 0.9	3.6 ± 1	3.6 ± 0.8	3.4 ± 0.9	3.3 ± 0.9	3.8 ± 1.1

Triglycerides (mmol/L)	1.2 (0.9,1.7)	1.2 (0.9,1.7)	1.3 (0.9,1.8)	1.4 (1.0,2.1)	1.3 (0.7,2.1)	1.6 (1.1,2.3)	1.1 (0.8, 1.6)	1.1 (0.8, 1.6)	1.3 (1.0, 1.8)
DBP (mmHg)	78.7 ± 11.3	76.4 ± 11.7	74.5 ± 11.5	77.6 ± 9.9	79.2 ± 11.0	77.9 ± 10.1	78.7 ± 11.4	81.3 ± 11.1	82.0 ± 11.0
SBP (mmHg)	134.2 ± 20.6	131.9 ± 20	125.3 ± 21.4	133.4 ± 18.4	141 ± 22.3	130.9 ± 18.7	135.0 ± 20.2	132.7 ± 18.6	134.2 ± 20.7

[1] Mean ± SD; median (Q1, Q3)

[2] SEED cohorts consist of a collection of three cohorts: Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Participants of the SEED cohorts were not required to fast. LDL cholesterol was measured in the Singapore Chinese Eye Study and Singapore Indian Eye Study, and calculated in the Singapore Malay Eye Study.

[3] We classified education level as follows: low – none, Primary or equivalent, intermediate – Secondary, diploma, Junior College, high school or equivalent, and high – college degree and above. The data for European cohorts could not be accessed.

[4] Only a subset of participants in MEC (N = 598, 531, 516, for Chinese, Malay, and Indian) had HbA1c measurements. To convert HbA1c from % to mmol/mol, first multiply HbA1c (%) by 10.93 and then substract 23.50.

Abbreviations: DBP, diastolic blood pressure, HbA1c, glycated hemoglobin A1c, HDL, high-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, SEED, SBP, systolic blood pressure, Singapore Epidemiology of Eye Diseases, Q1, quantile 1, Q3, quantile 3

Table 2. Associations between non-lipoprotein metabolic biomarkers and type 2 diabetes[1]

Metabolite	Chinese	Malay	Indian	Meta-analysis of Asians			Meta-analysis of Europeans			P-het
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value	P-het	OR (95% CI)	P-value	P-het	(Asians and Europeans)
Branched-chain amino acids										
Leucine	1.68 (1.41 - 2.00)	1.44 (1.19 - 1.73)	1.38 (1.16 - 1.64)	1.50 (1.35 - 1.66)	<0.0003	0.26	1.36 (1.27 - 1.46)	<0.0003	0.55	0.14
Isoleucine	1.68 (1.42 - 1.98)	1.43 (1.19 - 1.72)	1.33 (1.12 - 1.58)	1.48 (1.34 - 1.63)	<0.0003	0.15	1.36 (1.27 - 1.45)	<0.0003	0.76	0.17
Valine	1.54 (1.30 - 1.83)	1.35 (1.14 - 1.61)	1.36 (1.14 - 1.61)	1.42 (1.28 - 1.57)	<0.0003	0.48	1.25 (1.16 - 1.35)	<0.0003	0.39	0.05
Aromatic amino acids										
Phenylalanine	1.27 (1.07 - 1.51)	1.29 (1.04 - 1.59)	1.24 (1.04 - 1.47)	1.26 (1.14 - 1.40)	<0.0003	0.96	1.22 (1.14 - 1.31)	<0.0003	0.75	0.63
Tyrosine	1.34 (1.13 - 1.59)	1.21 (1.04 - 1.42)	1.22 (1.05 - 1.41)	1.25 (1.14 - 1.37)	<0.0003	0.64	1.21 (1.13 - 1.29)	<0.0003	0.79	0.56
Other amino acids										
Histidine	1.08 (0.91 - 1.27)	1.10 (0.91 - 1.32)	0.94 (0.80 - 1.11)	1.03 (0.93 - 1.14)	0.55	0.40	1.08 (1.00 - 1.16)	0.06	0.83	0.51
Alanine	1.35 (1.14 - 1.61)	1.15 (0.97 - 1.38)	1.27 (1.09 - 1.47)	1.26 (1.14 - 1.38)	<0.0003	0.45	1.25 (1.14 - 1.39)	<0.0003	0.19	0.96
Inflammation										
Glycoprotein acetyls	1.62 (1.38 - 1.90)	1.29 (1.05 - 1.58)	1.32 (1.15 - 1.52)	1.41 (1.28 - 1.55)	<0.0003	0.11	1.34 (1.25 - 1.43)	<0.0003	0.95	0.37
Fatty acids										

Total fatty acids	1.41 (1.22 - 1.64)	1.22 (1.03 - 1.45)	1.29 (1.12 - 1.49)	1.31 (1.20 - 1.44)	<0.0003	0.45	1.21 (1.13 - 1.29)	<0.0003	0.93	0.14
SFA (%)	1.16 (1.00 - 1.34)	1.22 (1.03 - 1.46)	1.09 (0.95 - 1.26)	1.15 (1.05 - 1.25)	0.002	0.62	1.21 (1.13 - 1.29)	<0.0003	0.56	0.36
MUFA (%)	1.52 (1.30 - 1.78)	1.48 (1.22 - 1.81)	1.32 (1.14 - 1.53)	1.43 (1.30 - 1.57)	<0.0003	0.42	1.38 (1.27 - 1.51)	<0.0003	0.28	0.63
PUFA (%)	0.66 (0.56 - 0.78)	0.67 (0.55 - 0.81)	0.78 (0.67 - 0.90)	0.71 (0.64 - 0.78)	<0.0003	0.30	0.72 (0.67 - 0.77)	<0.0003	0.48	0.78
n-6 PUFA (%)	0.64 (0.55 - 0.75)	0.68 (0.56 - 0.81)	0.76 (0.66 - 0.88)	0.70 (0.64 - 0.77)	<0.0003	0.27	0.70 (0.65 - 0.75)	<0.0003	0.52	0.96
Linoleic acid (%)	0.76 (0.65 - 0.88)	0.77 (0.65 - 0.92)	0.79 (0.68 - 0.92)	0.77 (0.71 - 0.85)	<0.0003	0.92	0.72 (0.67 - 0.77)	<0.0003	0.41	0.21
n-3 PUFA (%)	0.96 (0.83 - 1.10)	0.93 (0.78 - 1.10)	1.05 (0.90 - 1.23)	0.98 (0.89 - 1.07)	0.60	0.56	0.97 (0.91 - 1.04)	0.44	0.55	0.94
DHA (%)	0.95 (0.83 - 1.09)	0.97 (0.82 - 1.15)	1.03 (0.88 - 1.20)	0.98 (0.90 - 1.07)	0.67	0.78	0.96 (0.90 - 1.03)	0.30	0.46	0.75
Other metabolic biomarkers										
Sphingomyelins	1.01 (0.87 - 1.18)	0.92 (0.79 - 1.08)	1.07 (0.91 - 1.25)	1.00 (0.91 - 1.10)	0.98	0.44	0.90 (0.84 - 0.97)	0.007	0.70	0.08
Phosphoglycerides	1.24 (1.06 - 1.45)	1.11 (0.94 - 1.31)	1.19 (1.02 - 1.39)	1.18 (1.08 - 1.30)	<0.0003	0.60	1.08 (1.01 - 1.16)	0.03	0.67	0.14
Phosphatidylcholines	1.21 (1.04 - 1.42)	1.08 (0.92 - 1.28)	1.17 (1.01 - 1.36)	1.16 (1.06 - 1.27)	0.001	0.60	1.05 (0.98 - 1.13)	0.19	0.64	0.09
Cholines	1.15 (0.98 - 1.34)	1.03 (0.87 - 1.21)	1.14 (0.98 - 1.32)	1.11 (1.01 - 1.21)	0.03	0.58	1.02 (0.95 - 1.10)	0.63	0.71	0.16
Triglyceride by phosphoglyceride ratio	1.60 (1.37 - 1.86)	1.52 (1.24 - 1.85)	1.27 (1.11 - 1.45)	1.42 (1.30 - 1.55)	<0.0003	0.06	1.33 (1.26 - 1.42)	<0.0003	0.46	0.25
Citrate	1.15 (0.96 - 1.37)	1.05 (0.90 - 1.23)	1.38 (1.13 - 1.67)	1.16 (1.05 - 1.29)	0.003	0.11	0.91 (0.80 - 1.03)	0.13	0.11	0.00
Lactate	1.16 (0.98 - 1.37)	1.10 (0.91 - 1.34)	1.11 (0.95 - 1.29)	1.12 (1.02 - 1.24)	0.02	0.91	1.15 (0.98 - 1.35)	0.09	0.01	0.82
beta-hydroxybutyrate	1.22 (1.04 - 1.43)	1.10 (0.94 - 1.29)	1.28 (1.04 - 1.56)	1.19 (1.08 - 1.31)	0.001	0.48	0.99 (0.91 - 1.07)	0.80	0.79	0.01

Acetate	1.03 (0.84 - 1.27)	0.74 (0.50 - 1.10)	0.94 (0.81 - 1.09)	0.95 (0.85 - 1.06)	0.36	0.34	0.96 (0.88 - 1.05)	0.43	0.40	0.81
Acetoacetate	1.05 (0.91 - 1.22)	0.89 (0.74 - 1.07)	0.86 (0.73 - 1.02)	0.94 (0.86 - 1.04)	0.24	0.16	1.04 (0.96 - 1.12)	0.35	0.69	0.13
Albumin	1.28 (1.09 - 1.50)	1.26 (1.06 - 1.50)	1.17 (1.01 - 1.35)	1.23 (1.12 - 1.35)	<0.0003	0.68	1.12 (0.97 - 1.28)	0.13	0.10	0.25
Creatinine	0.96 (0.75 - 1.23)	0.71 (0.56 - 0.92)	0.96 (0.80 - 1.15)	0.89 (0.78 - 1.01)	0.07	0.14	0.97 (0.84 - 1.13)	0.72	0.06	0.36

[1] Other than fatty acids and lipoprotein measures, results for all metabolic biomarkers are shown here. For individual fatty acids, we only showed fatty acids expressed as a percentage of total fatty acids to avoid confounding by total fatty acids. All results for lipoprotein measures are displayed in Figure 1. Estimates are odds ratios (95% confidence intervals) per SD increase. The results for Chinese (n=2676), Malay (n=1872) and Indian (n=1845) participants were meta-analysed from the MEC and the SEED cohorts which consist of the Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Results for the European participants (n=14558) were meta-analysed from 3 prospective Finnish cohorts (FINRISK 2002, FINRISK 2012 and Health 2000). We adjusted or matched for age, age2 (only for MEC), sex, BMI and fasting glucose (MEC and Health 2000) or HbA1c (SEED cohorts, FINRISK 2002, FINRISK 2012). We accounted for multiple testing using Bonferroni correction and P-values < 0.0003 were considered statistically significant. P-het denotes Cochran Q heterogeneity.

Abbreviations: HbA1c, glycated hemoglobin A1c, MEC, Multiethnic Cohort, MUFA, monounsaturated fatty acids, n-3, omega-3, n-6 - omega-6, PUFA, polyunsaturated fatty acids, SEED, Singapore Epidemiology of Eye Diseases, SFA, saturated fatty acids


Asians
Finns
p-value < 0.0003
p-value ≥ 0.0003
Composite lipid measures
Total cholesterol
HDL2 cholesterol
HDL3 cholesterol
Remnant cholesterol
Esterified cholesterol
Free cholesterol
Lipoprotein cholesterol
VLDL cholesterol
IDL cholesterol
LDL cholesterol
HDL cholesterol
Extremely large VLDL cholesterol
Very large VLDL cholesterol
Large VLDL cholesterol
Medium VLDL cholesterol
Small VLDL cholesterol
Very small VLDL cholesterol
Large LDL cholesterol
Medium LDL cholesterol
Small LDL cholesterol
Very large HDL cholesterol
Large HDL cholesterol
Medium HDL cholesterol
Small HDL cholesterol
0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
Odds ratio for incident type 2 diabetes (95% CI)
per 1−SD increment in metabolite concentration
Lipoprotein particle size
VLDL size
LDL size
HDL size
Apolipoproteins
ApoB
ApoA1
ApoB by ApoA1
Lipoprotein triglycerides
VLDL triglycerides
IDL triglycerides
LDL triglycerides
HDL triglycerides
Extremely large VLDL triglycerides
Very large VLDL triglycerides
Large VLDL triglycerides
Medium VLDL triglycerides
Small VLDL triglycerides
Very small VLDL triglycerides
Large LDL triglycerides
Medium LDL triglycerides
Small LDL triglycerides
Very large HDL triglycerides
Large HDL triglycerides
Medium HDL triglycerides
Small HDL triglycerides
0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
Odds ratio for incident type 2 diabetes (95% CI)
per 1−SD increment in metabolite concentration